ZA200607531B - Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient - Google Patents

Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient

Info

Publication number
ZA200607531B
ZA200607531B ZA200607531A ZA200607531A ZA200607531B ZA 200607531 B ZA200607531 B ZA 200607531B ZA 200607531 A ZA200607531 A ZA 200607531A ZA 200607531 A ZA200607531 A ZA 200607531A ZA 200607531 B ZA200607531 B ZA 200607531B
Authority
ZA
South Africa
Prior art keywords
agomelatine
treatment
sleep disorders
medicaments intended
depressed patient
Prior art date
Application number
ZA200607531A
Other languages
English (en)
Inventor
Delalleau Bruno
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36200255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200607531(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of ZA200607531B publication Critical patent/ZA200607531B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200607531A 2005-09-09 2006-09-08 Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient ZA200607531B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0509207A FR2890562B1 (fr) 2005-09-09 2005-09-09 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime

Publications (1)

Publication Number Publication Date
ZA200607531B true ZA200607531B (en) 2008-05-28

Family

ID=36200255

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200607531A ZA200607531B (en) 2005-09-09 2006-09-08 Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient

Country Status (26)

Country Link
US (1) US20070060655A1 (pt)
EP (2) EP2295050A1 (pt)
JP (1) JP2007077148A (pt)
KR (2) KR20070029608A (pt)
CN (1) CN1927193B (pt)
AP (1) AP2008004379A0 (pt)
AR (1) AR056063A1 (pt)
AU (1) AU2006209372A1 (pt)
BR (1) BRPI0603762A (pt)
CA (1) CA2558762A1 (pt)
EA (1) EA014288B1 (pt)
FR (1) FR2890562B1 (pt)
GE (1) GEP20094602B (pt)
GT (1) GT200600409A (pt)
HK (1) HK1100481A1 (pt)
MA (1) MA28506B1 (pt)
MX (1) MXPA06010233A (pt)
NO (1) NO20064050L (pt)
NZ (1) NZ549726A (pt)
PE (1) PE20070333A1 (pt)
SG (1) SG146451A1 (pt)
TW (1) TW200800148A (pt)
UA (1) UA81573C2 (pt)
UY (1) UY29777A1 (pt)
WO (1) WO2007028905A1 (pt)
ZA (1) ZA200607531B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918372B1 (fr) * 2007-07-02 2009-08-28 Servier Lab Nouveaux derives naphtaleniques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2918370B1 (fr) * 2007-07-02 2009-08-28 Servier Lab Nouveaux derives naphtaleniques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN102190595A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
CN101991559B (zh) * 2010-11-25 2012-04-18 天津市汉康医药生物技术有限公司 一种稳定的阿戈美拉汀胶囊药物组合物
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
WO2013119605A1 (en) * 2012-02-07 2013-08-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Promoting sleep using at1 receptor blockers
CN102552211B (zh) * 2012-02-16 2013-07-17 福建广生堂药业股份有限公司 一种阿戈美拉汀的制剂组合物及其制备方法
HUE036989T2 (hu) 2013-06-06 2018-08-28 Zentiva Ks Agomelatin készítmény, amely agomelatint ko-kristály formájában tartalmaz
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
EP2856934A1 (en) * 2013-10-04 2015-04-08 Les Laboratoires Servier Biomarkers for the prediction of long term remission in depression
CN103655499B (zh) * 2013-12-23 2015-07-22 天津泰普药品科技发展有限公司 一种稳定的晶x型阿戈美拉汀片剂及其制备方法
CN103690499B (zh) * 2013-12-23 2015-05-06 天津泰普药品科技发展有限公司 一种稳定的晶i型阿戈美拉汀片剂及其制备方法
CN104523639B (zh) * 2014-12-11 2017-03-22 扬子江药业集团四川海蓉药业有限公司 一种阿戈美拉汀片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
US20050164987A1 (en) * 2003-12-24 2005-07-28 Barberich Timothy J. Melatonin combination therapy for improving sleep quality
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
US7645905B2 (en) * 2005-08-03 2010-01-12 Les Laboratoires Servier Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7635721B2 (en) * 2005-08-03 2009-12-22 Les Laboratoires Servier Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7358395B2 (en) * 2005-08-03 2008-04-15 Les Laboratories Servier Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
NO20064050L (no) 2007-03-12
HK1100481A1 (en) 2007-09-21
CN1927193B (zh) 2011-01-05
FR2890562A1 (fr) 2007-03-16
KR20070029608A (ko) 2007-03-14
KR20080103043A (ko) 2008-11-26
SG146451A1 (en) 2008-10-30
EP2295050A1 (fr) 2011-03-16
MA28506B1 (fr) 2007-04-03
BRPI0603762A (pt) 2007-05-15
CA2558762A1 (fr) 2007-03-09
CN1927193A (zh) 2007-03-14
UA81573C2 (en) 2008-01-10
EA014288B1 (ru) 2010-10-29
TW200800148A (en) 2008-01-01
AU2006209372A1 (en) 2007-03-29
AP2008004379A0 (en) 2008-04-30
FR2890562B1 (fr) 2012-10-12
UY29777A1 (es) 2006-10-31
PE20070333A1 (es) 2007-06-02
MXPA06010233A (es) 2007-03-08
GEP20094602B (en) 2009-02-10
EA200601449A1 (ru) 2007-04-27
EP1762237A1 (fr) 2007-03-14
JP2007077148A (ja) 2007-03-29
GT200600409A (es) 2007-04-30
US20070060655A1 (en) 2007-03-15
WO2007028905A1 (fr) 2007-03-15
NZ549726A (en) 2008-03-28
AR056063A1 (es) 2007-09-19

Similar Documents

Publication Publication Date Title
ZA200607531B (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient
IL184371A (en) Use of an anti il-31ra antibody in the manufacture of a medicament for treating skin disorders
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
PL1912650T3 (pl) Zastosowanie flibanseryny w leczeniu otyłości
HK1170429A1 (en) Alpha aminoamide derivatives useful in the treatment of cognitive disorders
IL178815A0 (en) The treatment of respiratory disease
IL178827A0 (en) Use of reboxetine for the treatment of pain
AP2488A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
LT1807156T (lt) Naujos farmacinės kompozicijos, naudingos nemigos gydyme
GB0410399D0 (en) The treatment of respiratory disease
EP1838316A4 (en) MACROCYCLIC ANALOGUES USEFUL FOR THE TREATMENT OF IMMUNOREGULATION DISORDERS AND RESPIRATORY DISEASES
IL198134A (en) A combination of antipsychotic drugs and tetracyclines to treat psychiatric illnesses
AP2656A (en) Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
TWI370735B (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
IL193944A0 (en) The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
IL177062A0 (en) Use of 14, 15 - dihydro- 20,21 - dinoreburnamenin-14-ol for the treatment and/or prevention of serious depression and sleep/waking cycle disorders
HK1125634A1 (en) Pharmaceutical for use in the treatment of ureterolithiasis
SI2030622T1 (sl) Indikacija odmerka progesterona pri zdravljenju travmatske poškodbe možganov
IL182406A0 (en) Use of an anti-atherothrombotic compound in obtaining medicaments intended for the treatment of vascular disorders
IL188104A (en) Use of intravenous mixtures of valenoctamide to prepare drugs for the treatment of bipolar disorders
ZA200900556B (en) Use of flumazenil in the manufacture of a medicament for the treatment of depressive disorders